Aditxt
ADTXAditxt, Inc. (NASDAQ: ADTX) is a United States-based biotechnology company developing technologies focused on monitoring and modulating the immune system. The company's operations are structured around two primary platforms: AditxtScore and Adimune. The AditxtScore platform is designed for immune profiling, utilizing a suite of assays to measure and score an individual's immune response to various pathogens, vaccines, and transplants. The Adimune platform is dedicated to immune tolerance induction, with research programs aimed at retraining the immune system to address autoimmune disorders and prevent transplant rejection. The company's therapeutic areas of interest include autoimmune diseases, such as type 1 diabetes and vitiligo, as well as organ transplantation. Aditxt's product pipeline, which is primarily in preclinical and clinical development stages, reflects this focus on immune system reprogramming. The company's business model involves advancing its proprietary platforms through internal research, collaborations, and potential licensing agreements. As a publicly traded entity, Aditxt reports its financial position and research progress through official Securities and Exchange Commission filings. The company's activities are centered on translating its immune monitoring and tolerance induction technologies into clinically validated tools and therapies.
ADTX · Stock Price
Historical price data
About
Aditxt, Inc. (NASDAQ: ADTX) is a United States-based biotechnology company developing technologies focused on monitoring and modulating the immune system. The company's operations are structured around two primary platforms: AditxtScore and Adimune. The AditxtScore platform is designed for immune profiling, utilizing a suite of assays to measure and score an individual's immune response to various pathogens, vaccines, and transplants. The Adimune platform is dedicated to immune tolerance induction, with research programs aimed at retraining the immune system to address autoimmune disorders and prevent transplant rejection. The company's therapeutic areas of interest include autoimmune diseases, such as type 1 diabetes and vitiligo, as well as organ transplantation. Aditxt's product pipeline, which is primarily in preclinical and clinical development stages, reflects this focus on immune system reprogramming. The company's business model involves advancing its proprietary platforms through internal research, collaborations, and potential licensing agreements. As a publicly traded entity, Aditxt reports its financial position and research progress through official Securities and Exchange Commission filings. The company's activities are centered on translating its immune monitoring and tolerance induction technologies into clinically validated tools and therapies.